Calculate the BODE Index for COPD prognosis. Combines BMI, airflow obstruction (FEV₁), dyspnea (mMRC), and exercise capacity (6MWD) for mortality prediction.
The BODE Index Calculator estimates prognosis in chronic obstructive pulmonary disease (COPD) by combining body mass index, airflow obstruction measured by FEV₁, dyspnea measured by the mMRC scale, and exercise capacity measured by 6-minute walk distance. It is a multidimensional score used in stable COPD.
Scores range from 0 to 10, with higher scores indicating worse prognosis. The index groups patients into quartiles with different survival estimates.
FEV₁ alone captures only one part of COPD severity. The BODE Index adds information about nutrition, dyspnea, and exercise tolerance.
It can support prognostic discussion, rehabilitation planning, and follow-up assessment alongside other COPD measures.
BODE Index = B + O + D + E B (BMI): ≤21 → 1 pt; >21 → 0 pts O (FEV₁% pred): ≥65 → 0; 50-64 → 1; 36-49 → 2; ≤35 → 3 D (mMRC): 0-1 → 0; 2 → 1; 3 → 2; 4 → 3 E (6MWD): ≥350m → 0; 250-349 → 1; 150-249 → 2; ≤149 → 3 Total Range: 0-10
Result: BODE 3 — Moderate Risk (Quartile 2)
FEV₁ 50% (1 pt) + 6MWD 300 m (1 pt) + mMRC 2 (1 pt) + BMI 24.2 (0 pts) = BODE 3. This places the patient in Quartile 2.
Celli et al. (NEJM 2004) validated the BODE Index in 876 COPD patients, demonstrating superior mortality prediction compared to FEV₁ alone. The index was applied to two independent cohorts from the US and Spain, showing consistent predictive power. Each 1-point increase in BODE was associated with a 34% increase in all-cause mortality and a 62% increase in respiratory mortality.
The BODE Index has applications in lung transplant evaluation (ISHLT guidelines), lung volume reduction surgery assessment, pulmonary rehabilitation outcomes, and clinical trial stratification. Changes in BODE after interventions serve as a composite endpoint that captures multiple dimensions of treatment effect.
Alternatives include the ADO Index (Age, Dyspnea, Obstruction), DOSE index (Dyspnea, Obstruction, Smoking, Exacerbations), and the GOLD combined assessment (symptoms + exacerbations). Each has different data requirements and strengths. BODE remains the best-validated tool for prognosis in stable COPD.
Last updated:
This calculator applies the original BODE framework by assigning points for body mass index, airflow obstruction by post-bronchodilator FEV1 percent predicted, dyspnea by the mMRC scale, and 6-minute walk distance. The four components are summed into the usual 0-10 total and then grouped into the BODE quartiles commonly used in COPD prognosis discussions.
The output is a stable-COPD prognostic aid rather than a stand-alone treatment plan. Exacerbation history, smoking status, oxygen need, imaging findings, and transplant or rehabilitation decisions still require a broader pulmonary assessment beyond the BODE total alone.
It is a prognostic tool for COPD that combines several measures instead of relying on FEV₁ alone.
It is often reviewed periodically and after major clinical changes such as exacerbations or rehabilitation.
Yes. In COPD, a low BMI can reflect poor nutritional status or cachexia and is associated with worse outcomes.
Referral thresholds vary by guideline and clinical context, so local transplant criteria should be used.
No. Other tools add exacerbation history, but the BODE Index does not.
Yes. Improvements in exercise capacity, dyspnea, nutrition, and overall COPD control can improve the score.